



Universiteit
Leiden
The Netherlands

From labelled to the optimal clinical dose: model-informed dose optimization in medical oncology practice

Tan, Z.

Citation

Tan, Z. (2026, March 31). *From labelled to the optimal clinical dose: model-informed dose optimization in medical oncology practice*. Retrieved from <https://hdl.handle.net/1887/4299937>

Version: Publisher's Version


License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4299937>

Note: To cite this publication please use the final published version (if applicable).

Section II

Closing the gap between the labelled
and optimal clinical dose with
publicly available data



Chapter 2

A systematic evaluation of the dosing regimens for approved targeted therapies and immune checkpoint inhibitors in metastatic renal cell carcinoma from a Project OPTIMUS perspective

Zhiyuan Tan, Swantje Völler, Aymara Sancho-Araiz,
Catherijne A. J. Knibbe, Dirk Jan A. R. Moes

ABSTRACT

Targeted therapies and immune checkpoint inhibitors have significantly improved survival outcomes in metastatic renal cell carcinoma (mRCC) but are often associated with high rates of adverse events, leading to dose reductions or treatment discontinuation. The FDA's recent initiative, Project OPTIMUS, emphasizes the importance of optimizing dosing regimens in oncology clinical development, and moves beyond the conventional maximum tolerated dose approach.

In this study, we aimed to review and redefine the approved dosing strategies for targeted therapies and immune checkpoint inhibitors in mRCC from the Project OPTIMUS perspective, including pazopanib, axitinib, cabozantinib, sunitinib, everolimus and nivolumab. A comprehensive summary of FDA clinical pharmacology reviews and clinical studies performed in routine clinical practice was conducted, alongside model-informed simulations of pharmacokinetic profiles with approved and alternative regimens.

Results demonstrated that actual tolerated doses in clinical practice were 46.1% to 86% lower than the approved dosages, with up to 75% of patients requiring dose adjustments. Model-informed simulations suggested that for most targeted therapies, a 14–50% dose reduction maintained comparable efficacy while improving tolerability. For nivolumab, simulations confirmed adequate drug exposure with the approved flat-dose regimens, without an increase of adverse effects.

In conclusion, we identified optimized dosing regimens that could improve drug tolerability while maintaining efficacy for approved targeted therapies and immune checkpoint inhibitors in mRCC. We suggest that these optimized dosing regimens should be considered for use in clinical practice and that the optimal exposure range be included in drug labels to support pharmacokinetically guided dose individualization in clinical practice.

Key words: Pazopanib, axitinib, cabozantinib, sunitinib, everolimus, nivolumab, dose reduction, dose optimization, dose selection

1. INTRODUCTION

1.1. Targeted therapies and immune checkpoint inhibitors for metastatic renal cell carcinoma

Metastatic renal cell carcinoma (mRCC) is the most common tumor of the urological system with poor prognosis.¹ Over the last decades, the treatment of mRCC has improved considerably with targeted therapies that block vascular endothelial growth factor (VEGF) or mechanistic target of rapamycin (mTOR) pathways. These therapies significantly improved objective response rates (ORR) and/or median progression free survival (PFS).² Since 2005, FDA and EMA approved several tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, axitinib, cabozantinib and the mTOR inhibitors everolimus and temsirolimus.³ Despite superior outcomes, tumors treated with small molecules are prone to develop drug resistance.⁴ Therefore, the treatment landscape is advancing towards novel immune checkpoint inhibitors (ICIs)-based strategies, either monotherapies or in combination.⁵ These therapies, which target the interaction between immune cells and tumor cells, have shown success in improving mRCC outcomes,⁶ with more durable efficacy compared to small molecules.⁷

1.2. Current problem in clinical development

The maximum tolerated dose (MTD), which is defined as the highest dose that does not cause dose-limiting toxicity (DLT, the same grade 3 or 4 adverse event (AE) in three or more patients⁸), has been the gold standard for dose selection in oncology dose-finding trials and is often adopted as the recommended Phase II dose (RP2D).⁹ However, targeted therapies demonstrate a different dose-response relationship compared to classic cytotoxic chemotherapy. More specifically, doses below the MTD may have similar efficacy to the MTD but may be associated with less toxicity.¹⁰ This idea is supported by high rates of dose reduction in routine clinical practice for many well-established targeted agents like cabozantinib and everolimus in mRCC at similar efficacy^{11,12} reflecting potentially inadequate dose selection prior to the registration trial.¹³ In addition, the traditional MTD paradigm often does not adequately evaluate other data, such as low-grade symptomatic toxicities (i.e., grade 1–2), dosage modifications, dose- and exposure-response relationships.¹⁰ An even larger inconsistency of exposure-response and exposure-toxicity relationship is observed in immune checkpoint inhibitors. For nivolumab, a flat exposure-response relationship was well established and has led to label change from weight-based dosing to alternative flat dosing strategy.¹⁴ It has even been shown that nivolumab 20 mg versus placebo every 3 weeks

(q3w) leads to improved 1-year overall survival (OS) in head and neck cancer,¹⁵ with 20 mg being considerably lower than the standard dose (3 mg/kg q2w or 240 mg q2w).

1.3. FDA Project OPTIMUS

The emerging evidence that targeted therapies are poorly-tolerated at the approved recommended MTD-based dosage was also noted by FDA.¹⁰ FDA reviewed the dose-related post-marketing requirements¹⁶ between 2010–2015 and found 33.3% new molecular entities (NMEs) had dose-related post-marketing requirements. As a result, in 2021 FDA project OPTIMUS¹⁰ was initiated, aiming to reform and improve dose optimization and selection in oncology drug development.¹⁷ The main recommendations are to collect and interpret all available clinical pharmacokinetic, pharmacodynamic, and pharmacogenomic data to identify the optimal dose rather than taking the MTD, as well as identifying a target dosage range early and then further evaluating several dosages.¹⁰ Another focus is to improve tolerability, which enables patients to remain on the effective targeted therapies or ICI treatment for longer period and results in reduced medical expenses.

In this report on six approved targeted therapies and ICI in mRCC (i.e. pazopanib, axitinib, cabozantinib, sunitinib, everolimus and nivolumab), we reviewed the approved dosages together with the dose-finding strategy, followed by an evaluation of routine clinical practice studies on the actual tolerated and effective doses and exposures observed in clinical practice. Finally, published pharmacokinetic (PK) models were assessed and selected for model-informed simulations to evaluate dosing from the perspective of optimal target achievement in the post-marketing context.

2. METHODS

2.1. Overall methods

For five targeted therapies (i.e. pazopanib, axitinib, cabozantinib, sunitinib and everolimus) and one ICI product (i.e. nivolumab) approved for mRCC, we first retrieved the approved dose and dose-finding strategy reported in the FDA clinical pharmacology review dossier. Secondly, routine clinical practice studies on dose reduction and alternative dose regimen information are presented and qualitatively summarized. Finally, published PK models of these targeted and immune checkpoint inhibitors are summarized and one of the models of each drug is selected for generating model-based optimal dose regimen that achieves the desired target exposure.

2.2. Literature search and PK model selection

The literature search is divided into three parts. First, FDA clinical pharmacology reviews of each drug were retrieved from FDA drug approval database (<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>).

Secondly, routine clinical practice studies including dose reduction or interruption information and studies that compared the approved dose with alternative regimens were retrieved. The approved dose, Dose Reduction Rate and dose intensity are summarized in Table 2.1.

Thirdly, published population pharmacokinetic (PK) modeling studies and reviews on exposure targets are used to perform model-informed simulations, summarized in Table 2.2. The dose regimens selected for the simulations are listed in Supplemental Table S2.1. Simulation regimens were chosen based on factors such as Dose Reduction Rate in routine clinical practice, the available dose strengths on the market and other possible doses that can result in achieving the exposure target. Detailed search terms and retrieved PK models are provided in Supplemental Materials. For drugs with more than one PK model, the following priorities are applied to select the preferred model for simulations: (1) The model derived from registration files, with external validation using routine clinical data (if available), is the preferred option; (2) If the preferred model is not available, the registration file model should be used; (3) If neither of the above models is available, a model based solely on routine clinical data should be considered; (4) Ideally, a model based on a larger population and without inter-occasion variability should be selected. Models that do not clearly define the occasions will be excluded; (5) Information on individuals included in the model who had concomitant therapy (potential drug-drug interaction, combination therapy) is excluded. Parameter estimates and covariates information of the selected models are provided in the Supplemental Materials.

2.3. Model-informed simulations to guide optimal dosing regimens

The approved and alternative dose regimens retrieved as described in 2.2 are used for model-informed simulations. To this end, 1000 virtual adult patients per regimen are generated by the copula covariate simulator (CoCoSim) web application (<https://cocosim.iacdr.leidenuniv.nl/>) based on the covariates in National Health and Nutrition Examination Survey dataset.¹⁸ If the model includes a covariate that cannot be generated by COCOSim, for example the prognosis score, random generation and assignment using the mean and standard deviation statistics from the original PK model publication will be used. Previously published reviews on exposure targets of these therapies are utilized

Table 2.1. Results on dose reduction and dose intensity in routine clinical practice studies

Study	Labelled dose	Number of patients	Starting dose in the studies	Dose Reduction Rate [% of patients]*	Dose intensity [mean dose [§]] OR Relative Dose intensity ^{&} (%)
Pazopanib					
	800 mg QD				
Shah et al. ²⁸		19	-	40%	-
Johnston et al. ²⁹		-	800 mg QD	60%	78%
Gaillard et al. ³⁰		18	800 mg QD (60% of patients [^])	-	672 mg QD
Masini et al. ¹⁵⁶		279	800 mg QD	36–66%	-
Axitinib					
	5 mg BID				
Johnston et al. ²⁹		-	5 mg BID	22%	95%
Gaillard et al. ³⁰		12	5 mg BID (60% of patients [^])	-	8.6 mg per day (4.3 mg BID)
Cabozantinib					
	60 mg QD				
Albiges et al. ⁵⁸		410	60 mg QD (71% of patients [^])	57%	-
Krens et al. ⁵⁹		59	60 mg QD (46% of patients [^])	58%	-
Campbell et al. ⁶¹		30	-	60%	-
Gan et al. ⁶²		413	-	50%	-
Martini et al. ⁵⁶		87	60 mg QD	68%	-
Prisciandaro ⁶⁴		17	60 mg QD	47%	-
McElwee et al. ⁶³		35	-	-	33 mg QD
Sunitinib					
	50 mg 4/2				
Gaillard et al. ³⁰		12	50 mg QD 4/2 (60% of patients [^])	-	34 mg QD
Porta et al. ¹¹³		85	50 mg QD 4/2	30%	-
Park et al. ¹¹²		270	50 mg QD 4/2	54%	-
Miyake et al. ⁸⁴		110	50 mg QD 4/2	93%	63%
Abd Ghafar et al. ⁷⁵		51	50 mg QD 4/2	61%	-
Noize et al. ⁸⁵		302	50 mg QD 4/2 (83.4% of patients [^])	65%	-
Everolimus					
	10 mg QD				
Nozawa et al. ¹²²		180	10 mg QD	40%	-

QD, once daily; BID, twice daily; 4/2, 4 weeks on and 2 weeks off treatment.

* The percentage of patients that experienced dose reduction during follow-up.

[§] The mean dose was calculated by dividing the sum of overall daily doses by number of days on therapy for all patients as reported by the studies.

[&] Relative dose intensity was calculated by dividing the actual daily dose (the mean of the sum of all daily doses divided by the number of days on therapy) by the starting dose as reported by the studies.

[^] with the remaining patients starting at lower dosages.

- No information reported by the study.

Table 2.2. Recommended starting dose based on labelled dose, routine clinical practice studies and model-informed results

Drug	Labelled dose	Dose in routine clinical practice*	Efficacy target concentration ^[REF]	Toxicity target concentration ^[REF]	Model-informed dose [§]	Conclusions and recommended starting dose ^{&}
Pazopanib	800 mg QD	600 mg QD	$C_{min,ss} \geq 20.5 \text{ mg/L}^{19,20}$	$C_{min,ss} < 46 \text{ or } 50 \text{ mg/L}^{19,20}$	600 mg QD	600 mg QD
Axitinib	5 mg BID	4 mg BID	$C_{min,ss} > 1.76 \text{ ng/mL}^{19,21}$	$C_{max,ss} > 40.2 \text{ ng/mL}^{19,21}$	5 mg BID	5 mg BID
Cabozantinib	60 mg QD	40 mg QD	$C_{min,ss} > 336 \text{ ng/mL}^{67}$	$C_{min,ss} < 750 \text{ ng/mL}^{67}$	60 mg QD * 2 days + 1 day skip; 40 mg QD	60 mg QD * 2 days + 1 day skip; 40 mg QD
Sunitinib [#]	50 mg QD 4/2	37.5 mg QD	$C_{min,ss} \geq 50 \text{ ng/mL}^{19}$	$C_{min,ss} < 100 \text{ ng/mL}^{19}$	50 mg QD 2/1	50 mg QD 2/1; 37.5 mg QD
Everolimus	10 mg QD	-	$C_{min,ss} > 10 \text{ ng/mL}^{19}$	$C_{min,ss} \leq 26.3 \text{ ng/mL}^{19}$	5 mg QD	5 mg QD
Nivolumab	3 mg/kg; 240 mg Q2W; 480 mg Q4W	-	$C_{min,ss} > 2.5 \text{ mg/L}^{136}$	/	3 mg/kg; 240 mg Q2W; 480 mg Q4W; 360 mg Q3W	3 mg/kg; 240 mg Q2W; 480 mg Q4W; 360 mg Q3W

QD, once daily; BID, twice daily; Q2W, once every 2 weeks; Q3W, once every 3 weeks; Q4W, once every 4 weeks; 4/2, 4 weeks on and 2 weeks off treatment; 2/1, 2 weeks on and 1 week off treatment; C_{min,ss}, trough concentration at steady state; C_{max,ss}, maximum concentration at steady state.

* The information of this column was taken from Table 2.1 and rounded to the nearest tablet/pill/vial strength.

[REF] The references for the efficacy and toxicity exposure targets.

[§] Derived from the model-informed simulations as described under paragraphs 3.3, 4.3, 5.3, 6.3, 7.3, using the selected PK models and exposure targets.

[&] The conclusions and recommended starting dose regimens are based on the previous columns and expert opinion if there is discrepancy between dose in routine clinical practice and model-informed dose.

- No solid evidence from routine clinical practice studies.

[#] Sunitinib exposure metric is the composite C_{min,ss} of both parent drug and main metabolite (sunitinib and SU12662).

/ No solid relationship available of nivolumab exposure with toxicities.

directly as simulation exposure targets.¹⁹⁻²¹ If multiple targets have been reported for one drug, the evidence evaluation hierarchy was applied: (1) the evidence from systematic review/meta-analysis; (2) the evidence from prospective studies; (3) the evidence from retrospective studies used in model-based exposure-response analysis; (4) if none of the above evidence could be retrieved, then no solid target could be used for simulation. In addition, percentage of target attainment (PTA) at steady state is summarized (the percentage of patients achieving the therapeutic target at steady state in the 1000 virtual patients). All simulations were performed in NONMEM 7.4.4. Further statistical comparison and visualization of exposure over time was performed in R.

3. PAZOPANIB

3.1. Approved dose and dose-finding strategy

Pazopanib was approved for mRCC in 2009 by the FDA²². Its primary mechanism of action can be described through its antiangiogenic properties via inhibition of the intracellular tyrosine kinase of VEGF receptor (VEGFR).²³ The recommended dose is 800 mg orally once daily (QD) without food. Pazopanib has a bioavailability range of 14% to 39% and is highly bound to protein (> 98.8%).²⁴ It is primarily metabolized by CYP3A4, therefore 200 mg QD is recommended for moderate hepatic impairment and its use in severe hepatic impairment should be avoided.²²

As for the dose-finding strategy of pazopanib, a Phase I dose escalation study involving 63 patients was performed where doses ranging from 50 to 2000 mg were evaluated in the dose-escalation phase and 300 mg BID, 400 mg BID, 800 mg QD were evaluated in the dose-expansion phase. Exposure seemed to increase proportionally with doses between 50 and 400 mg even though variability was high,²⁵ and dose-proportionality beyond 400 mg was marginal. Mean trough concentrations at steady state ($C_{\min,ss}$) on day 22 were similar for four dosing regimens (800 mg QD, 1000 mg QD, 300 mg BID, and 400 mg BID). Despite these findings, no MTD was reached during this study. Figure 2.1 (a) summarizes the number of responders for the different dose levels, showing that pazopanib doses ≥ 400 mg result in clinical response. Regarding safety, DLTs were identified in four out of 63 patients, occurring at 50 mg (2/9), 800 mg (1/3), and 2000 mg QD (1/3). These data led to the selection of 800 mg QD as the dose for registration trials.²⁶

Subsequently, exposure-response analysis conducted by FDA combined available data across trials²⁷ and stratified the patients into quartiles based on the $C_{\min,ss}$ for survival analysis. The survival curves of patients with different trough concentration-quartile

groups overlapped at several points, indicating an absence of an exposure-response relation for efficacy at the registered dose. In contrast, logistic regression analysis using data from the registration trial²⁶ demonstrated that the probability of Grade 3+ ALT elevations increased with increased pazopanib exposure (Figure 2.1 (b)), revealing a significant exposure-toxicity relationship.


3.2. Clinical routine practice studies of dose reduction and alternative regimens

In clinical practice, Dose Reduction Rate and related outcomes have been reported in several published studies (Table 2.1), ranged from 40%²⁸ to 60%^{29,30} in different studies, starting with 800 mg QD. Given the 200 mg per tablet formulation, alternative dosing strategies such as 600 mg QD and 400 mg QD have emerged as potential starting doses.

Evidence from retrospective studies highlights the potential benefits of dose adjustments. A study³¹ involving 179 patients with mRCC, almost exclusively receiving pazopanib as first-line treatment, found a statistically significant improvement in PFS and OS for patients who underwent dose reductions ($p < 0.0001$ for both PFS and OS), temporary interruption ($p < 0.0001$ for both PFS and OS) and schedule modifications ($p = 0.007$ for PFS and $p = 0.012$ for OS) compared to those who maintained the original dosing schedule.

Further support for dose reduction comes from a larger study by Lacovelli et al.,³² including 591 mRCC patients receiving pazopanib. Of these, 45.7% (270 out of 591 patients) required a dose reduction due to toxicity. Interestingly, patients who reduced their dose, achieved a median OS of 49.4 months, significantly longer than the 24.0 months observed in those who continued the standard dose (hazard ratio = 1.80, $p = 0.001$).

However, not all studies have demonstrated consistent outcomes. Grassi et al.³³ retrospectively compared the outcome of 69 mRCC patients treated with pazopanib, dividing them into three groups: group 1 included 34 patients who started with 800 mg QD and did not have a dose reduction, group 2 included 19 patients that started with 800 mg QD but reduced their dose to 400 or 600 mg QD due to toxicity, and group 3 included 16 patients that started with 400 or 600 mg QD due to poor prognosis. ORRs were 44%, 11% and 19% in the three groups, respectively. Discontinuation rates due to progressive disease (PD) were higher in groups 2 and 3 (42%, and 44%, respectively) than group 1 (28%). However, the authors noted that these differences might reflect the worse prognosis of groups 2 and 3, and therefore the results should be interpreted with caution.






Figure 2.1. Dose-exposure, dose/exposure-response or exposure-toxicity relationship of the investigated targeted therapies and ICI in clinical trials. **(a)** Pazopanib dose-response relationship based on Phase I trial data.²⁷ The plot represents the proportion of responders (best response – partial response or stable disease of any duration) vs. pazopanib dose. For this plot, a subset of patients who received once daily pazopanib dose were selected; **(b)** Pazopanib exposure-severe liver toxicity relationship based on registration study; **(c)** Axitinib dose-exposure relationship based on Phase I trial;⁴¹ **(d)** Axitinib exposure-severe hypertension relationship based on registration trial;⁴¹ **(e)** Cabozantinib exposure-response relationship in registration study;⁵⁵ **(f)** Cabozantinib exposure-severe hand-foot syndrome relationship in registration study;⁵⁵ **(g)** Sunitinib exposure-response relationship split by AUC in registration study.⁷² Red curve indicates the group of high sunitinib AUC_{tot} ($AUC_{tot} > 1900 \text{ ng}^*\text{h/mL}$) and blue curve indicates the group of low sunitinib AUC_{tot} ($AUC_{tot} < 1900 \text{ ng}^*\text{h/mL}$); **(h)** Sunitinib exposure-Grade3/4 neutropenia relationship in registration study;⁷² **(i)** Everolimus exposure-efficacy relationship divided by placebo and different $C_{min,ss}$ groups.¹¹⁹ The red curve indicates the placebo group and the blue curves indicate different $C_{min,ss}$ quantile group; **(j)** Everolimus exposure-anemia relationship.¹¹⁹ All sub-figures were replotted from the FDA CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW of pazopanib,²⁷ axitinib,⁴¹ cabozantinib,⁵⁵ sunitinib,⁷² everolimus.¹¹⁹

3.3. Model-informed dose based on published exposure target and PK model

The current exposure target of pazopanib, specifically the $C_{min,ss}$ target, ranges between 20.5 mg/L and 46–50 mg/L (Table 2.2). The upper threshold aimed at minimizing overall CTCAE ≥ 3 toxicity.²¹

In total, 4 pazopanib PK models^{34–37} were identified, and based on the model selection workflow as described in Methods section 2.2, we selected the model developed by our own group³⁷ for simulations. This model is based on routine clinical practice data while utilizing the model structure based on the large clinical trial datasets for marketing authorisation, and contained no covariates. Considering the current tablets available on the market (200 mg/tablet), simulations were performed at three starting dose levels: 800 mg QD, 600 mg QD and 400 mg QD. For the three simulated dosing regimens (Figure 2.2), although dose-related exposure differences are still discernible, there is an overlapping of the 90% prediction intervals (PI) due to high variability. While a starting dose of 400 mg QD may not result in the desired target for some patients, both 600 mg and 800 mg QD meet the $C_{min,ss}$ target of 20.5 mg/L. In addition, 600 mg

QD could also meet the safety threshold of 46 mg/L. The therapeutic target achievement calculation results (Supplemental Table S2.1) show that 600 mg QD results in a similar efficacy target attainment (75.6%) compared to 800 mg (85.9%), but with a lower incidence of toxicity (5.8% vs. 16.1%).




Figure 2.2. Model-informed pazopanib dose exploration using the model of Tan et al.³⁷ Blue dashed line indicates the efficacy target $C_{\min,ss} > 20.5$ mg/L. Red dashed line indicates the toxicity target $C_{\min,ss} < 46$ mg/L. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

4. AXITINIB

4.1. Approved dose and dose-finding strategy

Axitinib was approved by the FDA in 2012 for mRCC in patients who had failed one prior systemic therapy³⁸. Its mechanism of action is to inhibit VEGFR-1, 2 and 3 selectively.³⁹ The approved labelled oral dose is 5 mg twice daily (BID), with dose titration up to 7 mg BID and further to 10 mg BID, based on tolerability. The PK is dose-proportional within the clinical dose range.⁴⁰ Following oral administration, axitinib is absorbed rapidly, with maximum observed plasma concentrations ($C_{\max}$) reached within 4 hours. Its effective plasma half-life ranges between 2.5 to 6.1 h after a single oral dose.⁴¹ Axitinib has a mean absolute bioavailability of 58% and has > 99% protein-binding.⁴⁰

Dose selection was based on MTD criteria in a phase I PK and tolerability study that assessed various doses, including 10 mg QD, 15 mg QD, 5 mg BID, 10 mg BID, 20 mg BID, 30 mg BID. Substantial inter-individual variability was observed, with a coefficient of variation of 60% in area under the curve (AUC) following an axitinib dose of 5 mg BID.⁴¹

The dose-exposure relationship was generally linear (Figure 2.1 (c)) within the studied range based on the Phase I trial.⁴¹ Exposure-response studies pooled data from three phase II trials (178 patients) and the pivotal phase III trial (55 patients). Patients tolerating the initial 5 mg BID dose with upward titrations showed lower axitinib exposures at the starting dose, suggesting potential benefits from higher initial doses.⁴¹ However, insufficient data from the Phase III trial and other public databases prevented establishing a conclusive exposure-response relationship for PFS.⁴¹ In the exposure-toxicity evaluation, the logistic regression model demonstrated an exposure-dependent increase in hypertension (Figure 2.1 (d)), proteinuria, fatigue, and diarrhea.⁴¹

4.2. Clinical routine practice studies of dose reduction and alternative regimens

Several studies have evaluated axitinib tolerance in routine clinical practice setting (Table 2.1). Yasuoka et al.⁴² retrospectively collected data from 17 mRCC patients treated with axitinib at 5 mg of BID (10 mg/day) following first-line nivolumab therapy. All patients experienced AEs, with nine patients (52.9%) requiring dose reduction or treatment interruption. Similarly, another retrospective study,³⁰ which included 12 axitinib-treated patients, reported a median relative daily dose of 8.6 ± 2.6 mg/day with 50% of patients requiring dose reductions due to toxicity.

In contrast, a larger cohort study²⁹ reported a lower Dose Reduction Rate of 22%, despite a similar median starting dose of 5 mg BID. Notably, most patients in this cohort (63%) received axitinib as part of combination therapy, potentially influencing the lower rate of dose adjustment.

4.3. Model-informed dose based on published exposure target and PK model

Axitinib has a reported efficacy target of $C_{\min,ss} > 1.76$ ng/mL at 1–3 months after start of treatment from an exposure-response analysis based on clinical practice data⁴³ (Table 2.2). The cumulative incidence of DLT was significantly higher in patients with $C_{\max,ss} > 40.2$ ng/mL⁴⁴ which was selected as toxicity target (Table 2.2).

Three axitinib PK models were retrieved,^{45–47} all with the same model structure. The model published by Rini et al.⁴⁷ (Rini model⁴⁷) based on 17 clinical trials was selected for simulation due to the solid design, large sample size and robust parameter estimates. The simulated doses included 3, 5, 7 and 10 mg BID that were used as dose-titration/de-escalation in drug approval. Figure 2.3 depicts simulated PK profiles for the explored regimens. Numerical results for these simulations can be found in Supplemental Table S2.1. The approved starting dose of 5 mg BID results in achievement of $C_{\min,ss}$ target in

86.8% of the patients which is in line with the routine clinical practice summary that 5% of the 5 mg BID group would be beyond the target that may need dose de-escalation to 3 mg BID (Supplemental Table S2.1).




Figure 2.3. Model-informed axitinib dose exploration using Rini model.⁴⁷ Blue dashed line indicates the efficacy target $C_{min,ss} > 1.76$ ng/mL. Red dashed line indicates the toxicity target $C_{max,ss} < 40.2$ ng/mL. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

5. CABOZANTINIB

5.1. Approved dose and dose-finding strategy

Cabozantinib was approved by the FDA in 2012 for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy. This multi-kinase TKI exerts its effects by inhibiting several key pathways involved in cancer progression.⁴⁸ Specifically, cabozantinib targets the MET proto-oncogene (MET) and VEGFR2, reducing angiogenesis and diminishing drug resistance and metastasis.⁴⁹ The labelled dose is 60 mg QD fasted⁵⁰ since high-fat diet increases its bioavailability on average by 57%.⁵¹ Available tablet strengths include 60 mg, 40 mg and 20 mg. Following oral administration, cabozantinib showed dose-proportional increases in mean plasma concentrations. It has an exceptionally long terminal half-life ($t_{1/2}$) of approximately 99 hours, which supports once-daily dosing.

The dose selection was based on a phase I study that investigated 20, 40, 60 mg and 140 mg QD, with 60 mg QD chosen as starting dose. An exposure-response study⁵² was performed using data from a Phase III METEOR study,⁵³ where all patients received an initial dose of 60 mg QD. The analysis used a previously developed PK model⁵⁴ (PK model developed using healthy volunteers and patients with different tumor types) to predict average steady-state concentrations ($C_{avg,ss}$) for 60 mg QD (1125 ng/mL), 40 mg QD (750 ng/mL) and 20 mg QD (375 ng/mL) doses. Simulations showed hazard ratios (HR) for disease progression or death of 1.10 (40 mg) and 1.39 (20 mg) compared with 1125 ng/mL group. Based on these results, while 60 mg QD was considered superior for efficacy, the Kaplan-Meier plot (Figure 2.1 (e)) showed no significant survival differences between the exposure quartiles, suggesting inconclusive exposure-response relationship for PFS.⁵² Regarding safety, an exposure-response analysis revealed a dose-dependent increase in the risk of severe hand-foot syndrome (Figure 2.1 (f)). The predicted HR 2.21 (60 mg vs. 20 mg) and 1.49 (60 mg vs. 40 mg). Overall, while 60 mg QD dose showed better efficacy than lower doses it may not be optimal due to safety concerns and AE risks.⁵⁵

5.2. Clinical routine practice studies of dose reduction and alternative regimens

Martini et al.⁵⁶ included 87 mRCC patients, 33% of whom received cabozantinib as first-line therapy. Among the cohort, 68% required a dose reduction from 60 mg or started the treatment at a reduced dose without escalation. Patients receiving reduced doses were more likely to have ≥ 3 distant metastatic sites and ≥ 2 prior lines of systemic therapy compared to full dose patients. Regression analysis revealed a trend towards shorter OS (HR: 1.78, $p = 0.095$), shorter PFS (HR: 1.50, $p = 0.107$), and lower chance of objective response (HR: 0.42, $p = 0.149$) in reduced dose patients. However, these trends did not remain significant in multivariable analysis (OS HR: 1.20, $p = 0.636$; PFS HR: 1.23, $p = 0.4662$).

Recently, a retrospective analysis⁵⁷ of 71 mRCC patients revealed that 39.1% of patients were offered an alternative dose regimen due to intolerance. These alternative schedules included intermittent dosing patterns such as 14 days on treatment followed by 7 days off treatment, or 7 days on treatment followed by 4 days off treatment. Starting doses were 60 mg and 40 mg in 50.7% and 32.4% of patients, respectively. Compared to continuous dosing, alternative treatment schedules were associated with longer PFS (12.2 months vs. 6.1 months, $p = 0.014$). Toxicities were similar between the groups, with all-grade AE reported in 96.9% of patients on continuous dosing and 96% on alterna-

tive schedules. However, grade 3 or higher AEs occurred more often in the continuous dosing group (84.4% vs. 75%).

Additional studies have provided additional information regarding routine clinical practice tolerance of cabozantinib⁵⁸⁻⁶⁶ (Table 2.1). High rates of dose reduction were consistently observed across multiple retrospective analyses. For instance, a study with 410 mRCC patients⁵⁸ revealed that 57.0% of patients had a dose reduction, and 15.6% had an alternative dose schedule, with a median average daily dose of 40 mg. Similarly, another study involving 413 patients⁶² reported that approximately 50% of patients required dose reductions with an average relative dose of 33 mg (55.4% of the standard 60 mg dose). Dose reductions were associated with significantly longer time to treatment failure (TTF) and overall survival (OS) compared to those who did not require dose reductions (adjusted hazard ratios of 0.37, $p < 0.01$ for TTF and 0.46, $p = 0.04$ for OS).

Consistent findings were reported by Krens et al.,⁵⁹ who observed a Dose Reduction Rate of 58% and improved progression-free survival (PFS) for patients with dose reductions (65 vs. 31 weeks, $p = 0.001$). Smaller studies also reported Dose Reduction Rate ranging from 47% to 57%, showing that dose reductions are common and potentially beneficial in routine clinical practice settings.^{61, 64, 65}

5.3. Model-informed dose based on published exposure target and PK model

Cabozantinib is suggested to have a therapeutic window⁶⁷ of $C_{\min,ss} > 336$ ng/mL and $C_{\min,ss} < 750$ ng/mL (Table 2.2), though these values have not yet been widely accepted. Several PK models developed with clinical trial data were retrieved.^{52, 54, 68, 69} The model adapted from the FDA registration file⁶⁸ for mRCC with routine clinical data (Tan model⁵¹) was selected which did not include other tumor types and could better reflect the routine clinical setting. Results of simulated regimens with this model⁵¹ are shown in Figure 2.4. The approved 60 mg QD starting dose exhibited substantially higher exposure than desired $C_{\min,ss}$ target for both efficacy and safety while an alternative dose of 40 mg QD seems to maintain the balance between efficacy and safety in a better way. Taking into consideration the flat-pricing strategy of cabozantinib for all available strengths (the 20-mg tablet, 40-mg tablet, and 60-mg tablet share exactly the same price), another starting dose of 60 mg QD given 2 days and skip 1 day could not only offer the same target achievement compared to the 60 mg QD continuous dose (35.6% versus 20.8%, Supplemental Table S2.1) but also save drug expenses.⁵¹




Figure 2.4. Model-informed cabozantinib dose exploration using model of Tan et al.⁵¹ Blue dashed line indicates the efficacy target $C_{min,ss} > 336$ ng/mL. Red dashed line indicates the safety target $C_{min,ss} \leq 750$ ng/mL. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

6. SUNITINIB

6.1. Approved dose and dose-finding strategy

Sunitinib was among the first approved TKIs by the FDA in 2006 indicated for all mRCC patients. Sunitinib was identified as a potent inhibitor of VEGFR-1, -2, FLT3, KIT, PDGFR with antitumor and antiangiogenic activities.⁷⁰ The approved oral dose is 50 mg QD with 4 weeks on and 2 weeks off (4/2).⁷¹ It is slowly absorbed, reaching peak concentrations (T_{max}) between 6 and 12 hours, regardless of food intake. After absorption, sunitinib undergoes CYP3A4 mediated de-ethylation metabolism, producing SU012662, an active and equipotent metabolite. This metabolite contributes approximately 23–37% of the total AUC of the parent drug. The elimination half-life ($t_{1/2}$) of the parent compound and the metabolite are prolonged, with values of 40–60 hours and 80–100 hours, respectively.⁷² The PK models have shown significant inter-individual variability, with estimated coefficient of variation (%) of 21–71% for CL and 25–60% for AUC.⁷²

Dose finding studies for sunitinib began with a phase I study in solid tumors, testing doses from 50 mg once every other day (QOD) to 150 mg QD.⁷³ Based on dose-linearity and DLT observed at the next dose level of 75 mg QD 4/2, 50 mg QD was chosen for further development.⁷²

Following phase I, two single-arm studies were conducted to evaluate the PK and PD relationship in mRCC patients. Exposure, measured as the combined steady state AUC of sunitinib and SU012662 (AUC_{tot}) was evaluated in relation to both the efficacy and safety endpoint. For efficacy, time to tumor progression was used as the primary endpoint. Non-parametric Kaplan-Meier curves and parametric time-to-event modeling showed no clear exposure-response relationship for either AUC_{tot} or parent AUC alone. However, when Kaplan-Meier plots were stratified by exposure (low AUC [$AUC_{tot} < 1900$ ng*h/mL] and high AUC [$AUC_{tot} > 1900$ ng*h/mL]), the high AUC group appeared to show slightly longer time to progression and improved OS according to Figure 2.1 (g).⁷² For safety, logistic regression revealed significant exposure-toxicity relationships across multiple endpoints, including grade 3/4 neutropenia (Figure 2.1 (h)).⁷² In further Phase III registration trial, only 50 mg QD 4/2 was used. Dose reduction was seen in 32% of the patients,⁷⁴ and despite the relative high response rates across the exposure levels, there was no apparent exposure-partial response observed at 50 mg QD 4/2.⁷²

6.2. Clinical routine practice studies of dose reduction and alternative regimens

In clinical practice, a substantial number of studies have evaluated alternative regimens for sunitinib^{32, 75-110} (detailed information is summarized in Supplemental Material 2.2). Among these, 23 studies^{32, 88-110} compared outcomes between the standard regimen and various alternative regimens. The most commonly studied alternative dose was 50 mg 2 weeks on and 1 week off (2/1) as alternative regimen (50 mg 2/1), which provides the same overall dose as 50 mg 4/2. A meta-analysis has summarized these studies and compared the efficacy and safety of the 50 mg 2/1 with standard 50 mg 4/2 dosing.¹¹¹ It demonstrated that initiating treatment with 50 mg 2/1 significantly prolonged PFS compared to 50 mg 4/2 (HR: 0.75 [95% CI: 0.60–0.94]), while no difference was seen for OS. Additionally, switching from 50 mg 4/2 to 50 mg 2/1 resulted in a trend towards improved PFS (HR: 0.4 [95% CI: 0.14–1.12]). In terms of safety, the standard dose 50 mg 4/2 was associated with significantly higher odds of Grade 3–4 hand-foot syndrome compared with the alternative 50 mg 2/1 (OR:0.33 [95% CI 0.12–0.79]).

Other reduced or alternative regimens have also been reported. Boegemann et al.⁸⁹ conducted a retrospective analysis including 297 mRCC patients receiving sunitinib as

first-line therapy, comparing those who remain on 50 mg 4/2 standard dose with those who underwent subsequent treatment modification to 37.5 mg 4/2, 25 mg 4/2 or 50 mg 2/1. Patients with treatment modifications achieved significantly better outcomes compared to the standard regimen, including median time to progression (15.1 versus 3.9 months; $p < 0.0001$), PFS (15.1 versus 6.0; $p < 0.0001$), and OS (38.1 versus 13.7; $p < 0.0001$). However, the modification group experiences a higher frequency of AE, including diarrhea (34%/17%), fatigue (30%/11%), hand foot syndrome (28%/10%), and stomatitis (20%/6%).

Another study, Ohba et al.,¹⁰¹ compared a reduced regimen of 50 mg QOD dose with 50 mg 4/2. Median PFS and OS were significantly longer in the 50 mg QOD group compared with the 50 mg 4/2 group (27.6 vs. 6.2 and 87.1 vs. 24.6 months, respectively). The incidence of dose interruption caused by AE was significantly lower in the QOD group than in the standard group (28.1% vs. 56.3%, $p = 0.042$).¹⁰¹

An alternative regimen of 37.5 mg 4/2 as starting dose was also explored in two studies in Asian people.^{107, 108} These studies found no significant differences in overall survival from treatment initiation ($OS_{\text{initiation}}$), overall survival from the first documented metastasis (OS_{total}), or PFS between the standard and attenuated dose regimens ($OS_{\text{initiation}}$: 18.3 vs. 16.5 months, respectively; $p = 0.54$; OS_{total} : 27.4 vs. 21.8 months, respectively; $p = 0.45$; PFS: 6.7 vs. 7.9 months, respectively; $p = 0.64$). These findings were consistent with routine clinical outcomes observed in studies involving Caucasian populations. Importantly, the attenuated regimen was associated with a significant lower incidence of severe toxicities, dose delays, and dose reductions compared to standard regimen. As depicted in Table 2.1, the Dose Reduction Rate for sunitinib with the initial 50 mg QD 4/2 has been reported to range from 30% to 92.7% according to the evidence from routine clinical practice.^{30, 75, 84, 85, 112, 113} The mean dose intensity has been reported to be approximately 34 mg QD,³⁰ aligning with the alternative 37.5 mg QD regimen.

6.3. Model-informed dose based on published exposure target and PK model

Table 2.2 summarized the established therapeutic target range of combined sunitinib parent drug and metabolite SU12662 from $C_{\text{min,ss}}$ 50 to 100 ng/mL, based on exposure-response and exposure toxicity analysis from clinical practice patients.^{114, 115} Several PK models were identified for both sunitinib and SU12662. The Diekstra model,¹¹⁶ consisting of a two-compartment model for sunitinib and a biphasic distribution for SU12662, was selected due to a rigorous prospective design and good model performance. 50 mg QD 2/1 could result in a better target attainment than the approved 50 mg QD 4/2 regimen

(Figure 2.5). These findings are in line with what was observed in different clinical studies reported in 6.2. The therapeutic target achievement calculation results (Supplemental Table S2.1) show that 50 mg QD 2/1 achieves a similar target attainment (74%) compared to 50 mg QD 4/2 (75%), but with a lower incidence of toxicity (2% vs. 14%).




Figure 2.5. Model-informed sunitinib dose exploration with Diekstra model.¹¹⁶ Blue dashed lines indicate the efficacy target $C_{min,ss} > 50$ ng/mL. Red dashed lines indicate the safety target $C_{min,ss} \leq 100$ ng/mL. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

7. EVEROLIMUS

7.1. Approved dose and dose-finding strategy

Everolimus was approved by FDA in 2009 for patients with advanced RCC after failure of treatment with sunitinib or sorafenib. Everolimus is an oral protein kinase inhibitor of the mTOR signal transduction pathway.¹¹⁷ The labelled dose for advanced RCC is 10 mg QD.¹¹⁸ After oral administration, everolimus is absorbed with T_{max} of approximately 1–2 hours.¹¹⁹ The drug exhibits a dose-proportional AUC across the dose range of 5–70 mg. Nearly complete inhibition of S6 phosphorylation, which is the major mediator of anti-tumoral effects exerted by everolimus,¹²⁰ at a dose of 10 mg/day and 50 mg/week, led to the recommendation that these doses should be explored further.¹¹⁹

Dose-finding studies began with a phase I trial that evaluated both weekly regimens (5, 10, 20, 30, 50, 70 mg) and daily regimens (5 and 10 mg). These studies identified 10 mg QD as an appropriate dose based on pharmacokinetic properties and clinical safety. In the pivotal trial,¹²¹ all patients were treated with 10 mg QD. FDA reviewers¹¹⁹ conducted an exposure-response analysis using $C_{\min,ss}$ and PFS data. The analysis revealed similar median PFS across all $C_{\min,ss}$ subgroups (Figure 2.1 (i)), indicating no apparent exposure-response relationship for efficacy. Similarly, no trend was observed when AE were plotted against $C_{\min,ss}$ ¹¹⁹ as shown in Figure 2.1 (j) for anemia. These findings raised concerns about the appropriateness of 10 mg QD dose as starting point for routine clinical practice, given the unclear dose-response or dose-toxicity relationship. Available everolimus tablet strengths are 2.5, 5 and 10 mg for cancer patients.

7.2. Clinical routine practice studies of dose reduction and alternative regimens

Evidence from clinical routine practice regarding everolimus in the mRCC patients is limited (Table 2.1). A retrospective study¹²² included 180 mRCC patients mostly treated with everolimus as second-line therapy.¹²² The study found that patients who required dose reductions due to AE experienced a longer time to failure (4.2 months; 95% CI 3.4–5.0) than patients without dose reduction (1.7 months; 95% CI 1.0–2.3). These findings align with the observations made by FDA, as discussed in section 7.1. Another study reported the Dose Reduction Rate to be 6.2%¹²³ but due to a very short follow-up time of 28 days, it was excluded from the final summary.

7.3. Model-informed dose based on published exposure target and PK model

As shown in Table 2.2, everolimus has a published $C_{\min,ss}$ target between 10 ng/mL and 26.3 ng/mL based on a model-based analysis with pooled Phase II/III clinical trials data.¹²⁴ Only one everolimus PK model could be retrieved¹²⁵ (Tanaka model¹²⁵), based on a prospective cohort routine clinical study in mRCC patients. Another model that was based on thyroid cancer exhibited same model structure with comparable simulation results.¹²⁶ Results of simulated regimens (displayed in Supplemental Table S2.1) are shown in Figure 2.6. The approved 10 mg QD starting dose exhibited higher exposure than the desired safety target while a half dose of 5 mg QD could have better therapeutic target achievement (55% vs. 42%, Supplemental Table S2.1). Overall, the approved 10 mg QD may not be suitable in routine clinical practice from both clinical evidence and simulation study. Optimizing the starting dose to 5 mg QD could be a more suitable alternative.




Figure 2.6. Model-informed everolimus dose exploration with Tanaka model.¹²⁵ Blue dashed lines indicate the efficacy target $C_{\min,ss} > 10$ ng/mL. Red dashed lines indicate the safety target $C_{\min,ss} \leq 26.3$ ng/mL. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

8. NIVOLUMAB

8.1. Approved dose and dose-finding strategy

Nivolumab, an immune checkpoint inhibitor, was approved for use as monotherapy in mRCC patients who have received prior anti-angiogenic therapy.¹²⁷ Its mechanism of action involves blocking the PD-1 receptor, thereby enhancing T-cell mediated immune responses against tumors.¹²⁸ The current recommended dose is either 240 mg every 2 weeks (Q2W) or 480 mg every 4 weeks (Q4W).¹²⁹ Nivolumab clearance is linear over the dose range of 0.3–10 mg/kg,¹³⁰ and time-dependent, with decreasing clearance over prolonged treatment.¹³⁰ Evidence supporting these dosing regimens was summarized in the EMA's Clinical Pharmacology Summary,¹³¹ as no specific FDA review for this indication was available.

Dose selection was informed by early clinical studies. A large phase Ib open-label, dose-escalation, cohort-expansion study evaluated nivolumab's anti-tumor activity and safety across multiple tumor types including mRCC. Patients received doses of 1 mg/kg or 10 mg/kg,¹³² and no MTD was observed, even at the highest dose. The safety profile was consistent across dose levels, with similar nature, frequency and severity

of AE.¹³³ Exposure-response analysis¹³¹ included data from a phase II (CA209010) and a phase III trial (CA209025) comprising 569 mRCC patients. The analysis revealed a flat relationship between Cavg,ss and OS, indicating no significant exposure-response relationship for efficacy within the investigated dose range. Subsequent efficacy-bridging evaluations¹³⁴ were conducted to compare weight-based dosing and fixed dosing using pooled exposure-response modeling. These analyses, which included data from multiple tumor types including mRCC, support similarities in the benefit-risk profiles for 240 mg Q2W, 480 mg Q4W and 3 mg/kg Q2W. Based on these findings, all the three dose regimens were approved as labelled dose of nivolumab.

8.2. Clinical routine practice studies of dose reduction and alternative regimens

Evidence from routine clinical practice regarding nivolumab use in mRCC is relatively limited (Table 2.1). However, a prospective cohort study¹³⁵ involving 195 mRCC patients reported that those who completed all four cycles of nivolumab, with or without ipilimumab as first-line therapy, had significantly longer PFS and OS compared to those who received fewer than four cycles ($p < 0.0001$). Recently, model-informed simulations^{136, 137} have been conducted to explore the feasibility of extending the dosing intervals of nivolumab. These studies suggest that alternative regimens, such as 240 mg every 6 weeks (Q6W), could potentially reduce the financial burden while maintaining equivalent efficacy. For instance, in France, this alternative dosing schedule could potentially lower the annual treatment cost from €78,744 to €26,248.¹³⁶ These findings highlight the possibility of implementing extended dosing intervals as a cost-effective strategy without compromising clinical outcomes while clinical trials are warranted to confirm the non-inferiority of extended interval compared to standard regimen.

8.3. Model-informed dose based on published exposure target and PK model

As shown in Table 2.2, a previously used¹³⁶ putative minimal effective plasma concentration of 2.5 mg/L based on observed $C_{min,ss}$ in patients treated with nivolumab 0.1 mg/kg Q2W in a Phase I trial¹³⁸ is utilized. This concentration is about 60-fold higher than that required to occupy in-vitro more than 70% of PD-1 receptors on T cells (0.04 mg/L).¹³⁶ One PK model of nivolumab, Zhang model,¹³⁹ integrating 25 clinical trials including mRCC subpopulation was retrieved and used for simulation.¹³⁹ As shown in Figure 2.7, all approved flat-dose regimens, as well as weight-based dosing, achieved targets well. An alternative regimen of 360 mg every 3 weeks (Q3W) had 100% PTA, which could provide more flexibility for routine clinical practice. Numerical results of the simulations can be found in Supplemental Table S2.1.




Figure 2.7. Model-informed nivolumab dose exploration with Zhang model.¹³⁹ Blue dashed lines indicate the efficacy target $C_{\min,ss} > 2.5$ mg/L. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

9. LESSONS LEARNED

Recently, the FDA project OPTIMUS was initiated which is intended to assist sponsors in identifying an optimal dosage for new investigational drugs for the treatment of oncologic diseases during clinical development.¹⁰ Up to now, a well-controlled randomized registration trial was required using the MTD as selected dose for the phase III trial which was often unnecessarily high but still could achieve a favorable benefit-risk profile. However, project OPTIMUS further aims to increase the possibility of finding the optimal dosage beyond MTD before market approval since it is more challenging to conduct dosage optimization trials post-approval.¹⁴⁰ Nevertheless, according to the landmark learn-confirm concept proposed by Lewis Sheiner in 1997, a continuous learning process remains important after drug approval.¹⁴¹

In the current study, several mRCC target therapies were investigated including TKIs (pazopanib, axitinib, cabozantinib and sunitinib), an mTOR inhibitor (everolimus) and an immune checkpoint inhibitor (nivolumab). In line with project OPTIMUS, we combined data from both approval and post-approval to a) re-examine the approved dose and

dose-finding strategy, b) summarize routine clinical practice studies on best tolerated dose and c) explore model-informed optimal doses based on established therapeutic target (if available) or published evidence. Table 2.2 presents a final summary of the recommended starting dose regimens based of all the information retrieved in this systematic evaluation.

Our findings highlighted the limitation of the “one size fit all” dosing strategy applied to the four TKIs currently used in mRCC, except for axitinib. The starting dose of axitinib is 5 mg BID, with the option to titrate to 7–10 mg BID based on tolerability. However, its label does not recommend dose reductions below 5 mg BID even if the patient is already experiencing intolerability. The model-informed simulations of our study (Figure 2.3) highlight significant inter-individual variability in axitinib exposure, suggesting that not only dose titration but also dose de-escalation could have been considered at drug approval. In the case of pazopanib and cabozantinib, the approved doses appear higher than what many patients can tolerate in routine clinical practice. As shown in the simulations in Figures 2.2 (pazopanib) and 2.4 (cabozantinib), the exposure of approved dosages is higher than the toxicity threshold. Consequently, after the comprehensive evaluation presented here, the recommendation would be to reduce the starting dose to 600 mg QD for pazopanib and to 40 mg QD (or 60 mg 2 days on, 1 day off regimen) for cabozantinib (Table 2.2). By considering these dose reductions, a better balance between therapeutic exposure and safety could be achieved. For sunitinib, the approved 50 mg 4/2 regimen could potentially be replaced by a 50 mg 2/1 regimen, maintaining the same dose intensity but with lower toxicity and improved PFS in routine clinical practice. Overall, a common characteristic of TKIs is their complex oral absorption process¹⁴² and huge inter-individual variability of exposure,¹⁴³ which means that different doses may highly lead to considerably overlapping proportions of the 95% percentiles of the model-informed simulations from a population perspective. Therefore, starting at a lower dose with model-informed individualization to ensure that the patient stays within the therapeutic window could improve the treatment tolerability, lead to less drug discontinuation, and potentially decrease the risk of disease recurrence and treatment failure.

For the mTOR inhibitor everolimus, the dose finding process was similar to that of TKIs, with a flat dose-response relationship and clear exposure-toxicity relationship. However, everolimus was registered at a high dose of 10 mg QD, which could be an unnecessarily higher dose based on both exposure-response analysis from clinical trials data and routine clinical practice studies. A pre-published TDM target for everolimus (C_{min}

range of 10–26.3 ng/mL) generated from a model-based analysis of pooled clinical trials data,¹²⁴ and our simulation results depicted in Figure 2.10, indicated that 7.5 mg QD or 5 mg QD could result in a higher target attainment rate and therefore be more suitable starting regimens, rather than 10 mg QD.

When it comes to immune checkpoint inhibitors, nivolumab is currently used as monotherapy or in combination with ipilimumab or cabozantinib as one of the standard treatments in previously untreated mRCC patients. Although nivolumab has demonstrated significantly improved survival, due to its high cost, accessibility remains a challenge worldwide.¹⁴⁴ Despite the fact that limited routine clinical practice evidence was retrieved for mRCC patients, our simulations suggested that approved flat dose regimens could achieve sufficient drug exposure. Nevertheless, there are currently other dose optimization strategies being explored including reduced unit dose, less frequent schedule and/or shorter duration of treatment.¹⁴⁵ For example, a phase III randomized controlled trial is enrolling mRCC patients who have responded to nivolumab for one year, to either discontinue or continue treatment [JRCT1031200071]. For other tumor types, there are also many attempts to decrease the treatment intervals and treatment dose. One retrospective, non-randomized, study compared the efficacy of nivolumab 20 and 100 mg Q2W among patients with hepatocellular carcinoma.¹⁴⁶ The study indicated that 20 mg Q2W had a longer PFS than those who received 100 mg Q2W (4.5 months vs 2.3 months, $p = 0.007$).¹⁴⁶

To sum up, based on the results of all investigated targeted therapies and ICIs, except for axitinib, the approved fixed-dose regimens are either higher than the doses actually tolerated in routine clinical practice for small molecules^{27, 55, 72, 119} or are unnecessarily high due to the flat exposure-response/exposure-toxicity relationships, as in the case of nivolumab.¹³¹ Therefore, it is crucial that the focus should not only be identifying the optimal dose for the patient population as a whole, since considerable inter-patient variability in exposure will remain present with fixed dosing. Ideally the optimal exposure range should also be reported which can subsequently be used for pharmacokinetically guided dose individualization in the clinic.

Therapeutic alternatives for treating mRCC are increasing, with combination therapies including antiangiogenic agents and tyrosine kinase/mTOR/immune checkpoint inhibitors now considered as the gold standard, as supported by recent clinical studies.¹⁴⁷ These combination therapies have been evaluated using various trial designs, including sequential escalation, parallel escalation, monotherapy lead-in (intra-patient crossover)

and combination escalation.¹⁴⁸ However, despite these advancements, the dose-finding strategies and exposure-response relations for approved combination regimens in mRCC patients remain poorly defined. Recent recommendations advocate for the integration of a quantitative clinical pharmacology framework in dose-finding studies for combination therapy. This approach combines data from in vitro, preclinical in vivo and clinical trials, along with insight from competitive therapeutic landscape.¹⁴⁹ While promising, evidence from routine clinical practice for these combination therapies in mRCC remains scarce and was therefore not discussed in this study. Given the increasing reliance on combination therapies for mRCC treatment, it is critical to prioritize efforts in optimizing dose regimens. Such optimization will ensure that these therapies deliver their full potential in terms of efficacy and safety within routine clinical practice.¹⁵⁰

It is emphasized that the Phase III randomized controlled trials (RCTs) are the most rigorous way of determining whether a favorable benefit-risk relation exists between treatment regimen and outcome.¹⁵¹ In the current study, we leveraged and interpolated the dose regimens that had been investigated in early phase dose-finding trials with exposure simulations and include efficacy and toxicity data from routine clinical practice. This approach could be useful for future study designs or even serve as pivotal evidence to support the approval of untested doses which is as often applied in the pediatric population.¹⁵² In addition, the FDA recently published a guideline to support the development of alternative dosing regimens for anti-PD-1/PD-L1 antibodies that are derived using PK-based model-informed approach, if both the AUC and the C_{min} at the steady state for the test regimen are no more than 20% lower compared with the parameters of the reference dosing regimen used in registration study.¹⁵³ This shows that modelling and simulation is an important tool to develop alternative dose regimens suitable for application in clinical practice. This approach has, thus far, been employed to develop fixed dosing regimens and prolonged dosing intervals for the purposes of patient and prescriber convenience.¹⁵⁴ To sum up, the final recommendations of the present study, which are based on interpolation of regulatory registration data, routine clinical evidence and PK simulations, should be further evaluated in clinical practice and/or clinical trials.

Lastly, while our study provides valuable insights into dosing strategies for targeted therapies in mRCC, it also has certain limitations. Our analysis was limited to therapies with available data on three key points: 1) the approved dose and dose-finding strategy, 2) drug tolerance and alternative regimens in clinical practice, and 3) well-defined exposure targets for model-informed simulations. Consequently, combination therapies

and newer treatments such as tivozanib were not included. In the present study, routine clinical practice evidence was summarized and most of these observational studies have non-randomized, retrospective design which may be susceptible to confounding and selection bias.¹⁵⁵ Furthermore, although we selected a representative pharmacokinetic model for each drug based on a predefined approach, alternative models might yield different outcomes. Future research could expand on comparing different published models to refine our understanding. Despite these limitations, our study offers valuable guidance on optimizing dosing strategies to improve the efficacy and tolerability of targeted therapies and check point inhibitors in clinical practice.

10. CONCLUSION

This study comprehensively evaluates the opportunities of dose optimization of approved mRCC target therapies and immune checkpoint inhibitors in the context of project OPTIMUS. Through a combination of literature review, real world evidence on toxicity and efficacy, and model-informed simulations, we identified optimized dosing regimens that could improve drug tolerability while maintaining efficacy. We recommend that these optimized dosing regimens should be considered for further evaluation for existing therapies and that the optimal exposure range should be included in drug labels to support pharmacokinetically guided dose individualization in clinical practice.

REFERENCES

1. Pontes O, Oliveira-Pinto S, Baltazar F, Costa M. Renal cell carcinoma therapy: Current and new drug candidates. *Drug discovery today*. Jan 2022;27(1):304-314. doi:10.1016/j.drudis.2021.07.009
2. Medina López RA, Rivero Belenchon I, Mazuecos-Quirós J, Congregado-Ruiz CB, Couñago F. Update on the treatment of metastatic renal cell carcinoma. *World journal of clinical oncology*. Jan 24 2022;13(1):1-8. doi:10.5306/wjco.v13.i1.1
3. Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. *Nature Reviews Nephrology*. 2017/08/01 2017;13(8):496-511. doi:10.1038/nrneph.2017.82
4. Ravaud A, Gross-Goupil M. Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. *Cancer Treatment Reviews*. 2012/12/01/ 2012;38(8):996-1003. doi:https://doi.org/10.1016/j.ctrv.2012.01.003
5. Liu Y-F, Zhang Z-C, Wang S-Y, et al. Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review. *International Immunopharmacology*. 2022/09/01/ 2022;110:108900. doi:https://doi.org/10.1016/j.intimp.2022.108900
6. Gurram S, Al Harthy M, Ball MW. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update. *Discovery medicine*. May-Jun 2020;29(158):191-199.
7. Hizal M, Sendur MAN, Bilgin B, Akinci MB, Sener Dede D, Yalcin B. A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint. *Current medical research and opinion*. Apr 2020;36(4):625-635. doi:10.1080/03007995.2020.1716705

8. Ajithkumar TV, Hatcher HM. 25 - Clinical trials in cancer. In: Ajithkumar TV, Hatcher HM, eds. *Specialist Training in Oncology*. Mosby; 2011:355-359.
9. Le Tourneau C, Gan HK, Razak AR, Paoletti X. Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. *PloS one*. 2012;7(12):e51039. doi:10.1371/journal.pone.0051039
10. *Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases, Guidance for Industry* (2024).
11. Jänne PA, Kim G, Shaw AT, Sridhara R, Pazdur R, McKee AE. Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle. *Clinical cancer research : an official journal of the American Association for Cancer Research*. Jun 1 2016;22(11):2613-7. doi:10.1158/1078-0432.Ccr-15-2643
12. Verheijen RB, Atrafi F, Schellens JHM, et al. Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial. *Clinical Pharmacokinetics*. 2018/05/01 2018;57(5):637-644. doi:10.1007/s40262-017-0582-9
13. Shah M, Rahman A, Theoret MR, Pazdur R. The Drug-Dosing Conundrum in Oncology - When Less Is More. *The New England journal of medicine*. Oct 14 2021;385(16):1445-1447. doi:10.1056/NEJMp2109826
14. Bei D, Osawa M, Uemura S, et al. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers. *Cancer science*. Feb 2020;111(2):528-535. doi:10.1111/cas.14252
15. Patil VM, Noronha V, Menon N, et al. Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Jan 10 2023;41(2):222-232. doi:10.1200/jco.22.01015
16. Gendy JM, Nomura N, Stuart JN, Blumenthal G. US FDA's Dose Optimization Postmarketing Requirements and Commitments of Oncology Approvals and the Impact on Product Labels from 2010 to 2022: An Emerging Landscape from Traditional to Novel Therapies. *Therapeutic innovation & regulatory science*. Mar 2024;58(2):380-386. doi:10.1007/s43441-023-00606-1
17. Moon H. FDA initiatives to support dose optimization in oncology drug development: the less may be the better. *Translational and clinical pharmacology*. Jun 2022;30(2):71-74. doi:10.12793/tcp.2022.30.e9
18. Guo Y, Guo T, Knibbe CAJ, Zwep LB, van Hasselt JGC. Generation of realistic virtual adult populations using a model-based copula approach. *Journal of pharmacokinetics and pharmacodynamics*. Jun 6 2024;doi:10.1007/s10928-024-09929-4
19. Puisset F, Mseddi M, Mourey L, et al. Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer. *Cancers*. 2023;15(1):313.
20. Mueller-Schoell A, Groenland SL, Scherf-Clavel O, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. *European journal of clinical pharmacology*. Apr 2021;77(4):441-464. doi:10.1007/s00228-020-03014-8
21. Henriksen JN, Andersen CU, Frstrup N. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. Jun 2024;22(3):102064. doi:10.1016/j.clgc.2024.102064
22. FDA. Label of VOTRIENT (pazopanib) tablets.
23. Kasper B, Hohenberger P. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas. *Future oncology (London, England)*. Dec 2011;7(12):1373-83. doi:10.2217/fon.11.116
24. Pick AM, Nystrom KK. Pazopanib for the treatment of metastatic renal cell carcinoma. *Clinical therapeutics*. Mar 2012;34(3):511-20. doi:10.1016/j.clinthera.2012.01.014
25. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*. Jun 15 2009;15(12):4220-7. doi:10.1158/1078-0432.Ccr-08-2740
26. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. *New England Journal of Medicine*. 2013;369(8):722-731. doi:10.1056/NEJMoa1303989
27. Research CFDEA. Votrient (pazopanib) tablets clinical pharmacology and bipharmaceutics review.
28. Shah AY, Kotecha RR, Lemke EA, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. *European journal of cancer (Oxford, England : 1990)*. Jun 2019;114:67-75. doi:10.1016/j.ejca.2019.04.003

29. Johnston H, Deal AM, Morgan KP, Patel B, Milowsky MI, Rose TL. Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors. *Clinical genitourinary cancer*. Jun 2023;21(3):357-365. doi:10.1016/j.clgc.2023.02.007
30. Gaillard V, Lhuillier A, Bigot C, et al. Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*. Aug 2022;30(8):6583-6591. doi:10.1007/s00520-022-07088-1
31. Corianò M, Giannarelli D, Scartabellati G, et al. Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? Expert review of anticancer therapy. May 2023;23(5):545-554. doi:10.1080/14737140.2023.2200168
32. Iacovelli R, Cossu Rocca M, Galli L, et al. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. *Urologic oncology*. Sep 2017;35(9):541.e7-541.e13. doi:10.1016/j.urolonc.2017.05.007
33. Grassi P, Verzoni E, Ratta R, et al. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? *Drugs in R&D*. Sep 2017;17(3):461-467. doi:10.1007/s40268-017-0203-y
34. Bins S, Huitema ADR, Laven P, et al. Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. *Clinical pharmacokinetics*. May 2019;58(5):651-658. doi:10.1007/s40262-018-0719-5
35. Ozbey AC, Combarel D, Poinsignon V, et al. Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC. *Pharmaceuticals (Basel, Switzerland)*. Sep 15 2021;14(9) doi:10.3390/ph14090927
36. Yu H, van Erp N, Bins S, et al. Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. *Clinical pharmacokinetics*. Mar 2017;56(3):293-303. doi:10.1007/s40262-016-0443-y
37. Zhiyuan Tan SV, Anyue Yin, Amy Rieborn, Max Kramer, Mike Volwater, Hans Gelderblom, Tom van der Hulle, Catherijne Knibbe, Dirk Jan Moes. Population pharmacokinetic analysis of pazopanib in adult patients with metastatic renal cell carcinoma and soft tissue sarcoma. <https://www.page-meeting.org/default.asp?abstract=10553>
38. FDA. Label of INLYTA® (axitinib) tablets
39. Chen Y, Suzuki A, Tortorici MA, et al. Axitinib plasma pharmacokinetics and ethnic differences. *Investigational New Drugs*. 2015/04/01 2015;33(2):521-532. doi:10.1007/s10637-015-0214-x
40. Chen Y, Tortorici MA, Garrett M, Hee B, Klammerus KJ, Pithavala YK. Clinical Pharmacology of Axitinib. *Clinical Pharmacokinetics*. 2013/09/01 2013;52(9):713-725. doi:10.1007/s40262-013-0068-3
41. Research CFDEA. Inlyta® (axitinib) tablets clinical pharmacology and bipharmaeutics review.
42. Yasuoka S, Yuasa T, Fujiwara R, et al. Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer. *Anticancer research*. Nov 2020;40(11):6493-6497. doi:10.21873/anticancer.14671
43. Synowiec Z, Sobańska K, Synowiec T, Teżyk A, Tomczak P, Jablecka A. Axitinib Trough Concentration and its Influence on the Efficacy and Toxicity of Second-line Renal Cell Carcinoma Treatment. *Clin Genitourin Cancer*. Aug 2022;20(4):390.e1-390.e8. doi:10.1016/j.clgc.2022.03.006
44. Fukudo M, Tamaki G, Azumi M, Kakizaki H, Matsumoto S, Tasaki Y. Absorption of the orally active multi-kinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma. *Investigational New Drugs*. 2021/04/01 2021;39(2):595-604. doi:10.1007/s10637-020-01023-z
45. Chen Y, Rini BI, Bair AH, Mugundu GM, Pithavala YK. Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma. *Clin Pharmacokinetic*. Apr 2015;54(4):397-407. doi:10.1007/s40262-014-0207-5
46. Garrett M, Poland B, Brennan M, Hee B, Pithavala YK, Amantea MA. Population pharmacokinetic analysis of axitinib in healthy volunteers. *British journal of clinical pharmacology*. Mar 2014;77(3):480-92. doi:10.1111/bcp.12206
47. Rini BI, Garrett M, Poland B, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. *Journal of clinical pharmacology*. May 2013;53(5):491-504. doi:10.1002/jcph.73
48. Srigadha VK, Prabhaskar K, Noronha V, et al. Cabozantinib: A narrative drug review. *Cancer Research, Statistics, and Treatment*. 2023;6(1):74-87. doi:10.4103/crst.crst_9_23

49. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. *Molecular cancer therapeutics*. 2011;10(12):2298-2308.
50. FDA. Label of CABOMETYX™ (cabozantinib) tablets.
51. Tan Z, Völler S, Yin A, et al. Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens. *Clin Pharmacokinet*. Jun 14 2024;doi:10.1007/s40262-024-01379-y
52. Lacy S, Nielsen J, Yang B, Miles D, Nguyen L, Hutmacher M. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. *Cancer chemotherapy and pharmacology*. Jun 2018;81(6):1061-1070. doi:10.1007/s00280-018-3579-7
53. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *The Lancet Oncology*. Jul 2016;17(7):917-927. doi:10.1016/s1470-2045(16)30107-3
54. Lacy S, Yang B, Nielsen J, Miles D, Nguyen L, Hutmacher M. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types. *Cancer chemotherapy and pharmacology*. Jun 2018;81(6):1071-1082. doi:10.1007/s00280-018-3581-0
55. Research CFDEA. Cabometyx™ (cabozantinib) tablets clinical pharmacology and bipharmaceutics review. 2012.
56. Martini DJ, Evans ST, Liu Y, et al. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. *Clinical genitourinary cancer*. Feb 2022;20(1):53-59. doi:10.1016/j.clgc.2021.11.004
57. Bruchbacher A, Franke J, Alimohammadi A, Laukhtina E, Fajkovic H, Schmidinger M. Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma. *Clinical genitourinary cancer*. Sep 29 2023;doi:10.1016/j.clgc.2023.09.006
58. Albiges L, Fléchon A, Chevreau C, et al. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. *European journal of cancer (Oxford, England : 1990)*. Jan 2021;142:102-111. doi:10.1016/j.ejca.2020.09.030
59. Krens SD, van Erp NP, Groenland SL, et al. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer. *BMC cancer*. Mar 2 2022;22(1):228. doi:10.1186/s12885-022-09338-1
60. McGregor BA, Lalani AA, Xie W, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. *European journal of cancer (Oxford, England : 1990)*. Aug 2020;135:203-210. doi:10.1016/j.ejca.2020.05.009
61. Campbell MT, Bilen MA, Shah AY, et al. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. *European journal of cancer (Oxford, England: 1990)*. Nov 2018;104:188-194. doi:10.1016/j.ejca.2018.08.014
62. Gan CL, Dudani S, Wells JC, et al. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Cancer medicine*. Feb 2021;10(4):1212-1221. doi:10.1002/cam4.3717
63. McElwee JH, Gourdin TS, Mikoll J, Weeda E, Sion AM. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. Jun 2020;26(4):861-865. doi:10.1177/1078155219875509
64. Prisciandaro M, Ratta R, Massari F, et al. Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program. *American journal of clinical oncology*. Jan 2019;42(1):42-45. doi:10.1097/coc.0000000000000478
65. Procopio G, Prisciandaro M, Iacovelli R, et al. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. *Clinical genitourinary cancer*. Aug 2018;16(4):e945-e951. doi:10.1016/j.clgc.2018.03.014
66. Procopio G, Sepe P, Claps M, et al. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). *JAMA oncology*. Jun 1 2022;8(6):910-913. doi:10.1001/jamaoncol.2022.0238

67. Blanchet B, Xu-Vuilard A, Jouinot A, et al. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care. *British journal of cancer*. Apr 2024;130(6):961-969. doi:10.1038/s41416-024-02585-y
68. CDER. Clinical pharmacology and biopharmaceutics review(s) of cabometyx. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208692Orig1s000TOC.cfm
69. Nguyen L, Chapel S, Tran BD, Lacy S. Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma. *Journal of clinical pharmacology*. Nov 2019;59(11):1551-1561. doi:10.1002/jcph.1467
70. Le Tourneau C, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). *Therapeutics and clinical risk management*. Jun 2007;3(2):341-8. doi:10.2147/tcrm.2007.3.2.341
71. FDA. Label of SUTENT® (sunitinib malate) capsules.
72. Research CFDEA. Sutent® (sunitinib malate) capsules clinical pharmacology and biopharmaceutics review.
73. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Jan 1 2006;24(1):25-35. doi:10.1200/jco.2005.02.2194
74. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. *New England Journal of Medicine*. 2007;356(2):115-124. doi:doi:10.1056/NEJMoa065044
75. Abd Ghafar NK, Alip A, Ong TA, Yap NY, Saad M. Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience. *Journal of cancer research and therapeutics*. Oct-Dec 2018;14(6):1303-1311. doi:10.4103/0973-1482.189247
76. Ansari J, Fatima A, Fernando K, Collins S, James ND, Porfiri E. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience. *Oncology reports*. Aug 2010;24(2):507-10. doi:10.3892/or_00000886
77. Brunello A, Basso U, Sacco C, et al. Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study. *Annals of oncology : official journal of the European Society for Medical Oncology*. Feb 2013;24(2):336-342. doi:10.1093/annonc/mds431
78. Fujita T, Hirayama T, Nishi M, Matsumoto K, Yoshida K, Iwamura M. Outcome of third-line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma. *Molecular and clinical oncology*. Nov 2019;11(5):505-510. doi:10.3892/mco.2019.1924
79. Ishihara H, Takagi T, Kondo T, et al. Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma. *Japanese journal of clinical oncology*. Jul 1 2018;48(7):667-672. doi:10.1093/jjco/hyy078
80. Iwamoto K, Ishihara H, Takagi T, et al. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. *Medical oncology (Northwood, London, England)*. Apr 23 2018;35(6):78. doi:10.1007/s12032-018-1139-y
81. Josephs D, Hutson TE, Cowey CL, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. *BJU international*. Oct 2011;108(8):1279-83. doi:10.1111/j.1464-410X.2010.09990.x
82. Kawashima A, Tsujimura A, Takayama H, et al. Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma. *Medical oncology (Northwood, London, England)*. Dec 2012;29(5):3298-305. doi:10.1007/s12032-012-0236-6
83. Livne-Segev D, Gottfried M, Maimon N, et al. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors. *The Israel Medical Association journal : IMAJ*. Jun 2014;16(6):347-51.
84. Miyake H, Miyazaki A, Harada K, Fujisawa M. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. *Medical oncology (Northwood, London, England)*. Jun 2014;31(6):978. doi:10.1007/s12032-014-0978-4
85. Noize P, Grelaud A, Bay JO, et al. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study. *Pharmacoepidemiology and drug safety*. Dec 2017;26(12):1561-1569. doi:10.1002/pds.4228
86. Poprach A, Lakomy R, Bortlicek Z, et al. Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. *Drugs & aging*. Sep 2016;33(9):655-63. doi:10.1007/s40266-016-0390-1

87. Yildiz I, Ekenel M, Akman T, et al. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. *Anticancer research*. Aug 2014;34(8):4329-34.
88. Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. *The Journal of urology*. Mar 2014;191(3):611-8. doi: 10.1016/j.juro.2013.08.090
89. Boegemann M, Hubbe M, Thomaidou D, et al. Sunitinib Treatment Modification in First-Line Metastatic Renal Cell Carcinoma: Analysis of the STAR-TOR Registry. *Anticancer research*. Nov 2018;38(11):6413-6422. doi:10.21873/anticancer.13002
90. Bracarda S, Iacovelli R, Boni L, et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. *Annals of oncology : official journal of the European Society for Medical Oncology*. Oct 2015;26(10):2107-13. doi:10.1093/annonc/mdv315
91. Buti S, Donini M, Bersanelli M, Gattara A, Leonardi F, Passalacqua R. Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study. *Drugs in R&D*. Dec 2017;17(4):585-596. doi:10.1007/s40268-017-0209-5
92. Buti S, Donini M, Lazzarelli S, Passalacqua R. A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis. *Acta bio-medica : Atenei Parmensis*. Aug 2012;83(2):88-94.
93. Cheng W, Kletas V, Kollmannsberger C, de Lemos M. Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners*. Jan 2020;26(1):67-73. doi:10.1177/1078155219837333
94. Crumbaker M, Guminski A, Gurney H, Sabanathan D, Wong S, Pavlakis N. Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia. *Asia-Pacific journal of clinical oncology*. Apr 2018;14(2):e45-e49. doi:10.1111/ajco.12686
95. De Giorgi U, Scarpi E, Sacco C, et al. Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis. *Clinical genitourinary cancer*. Jun 2014;12(3):182-9. doi:10.1016/j.clgc.2013.11.005
96. Ezz El Din M. Sunitinib 4/2 Versus 2/1 Schedule for Patients With Metastatic Renal Cell Carcinoma: Tertiary Care Hospital Experience. *Clinical genitourinary cancer*. Jun 2017;15(3):e455-e462. doi:10.1016/j.clgc.2016.10.010
97. Makino K, Yoda K, Tomoishi J, Kume H. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases. *BMC research notes*. Dec 4 2014;7:872. doi:10.1186/1756-0500-7-872
98. Miyake H, Harada K, Miyazaki A, Fujisawa M. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib. *Medical oncology (Northwood, London, England)*. Mar 2015;32(3):78. doi:10.1007/s12032-015-0528-8
99. Miyake H, Matsushita Y, Watanabe H, et al. Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma. *Medical oncology (Northwood, London, England)*. Aug 20 2018;35(10):133. doi:10.1007/s12032-018-1195-3
100. Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. *European journal of cancer (Oxford, England : 1990)*. Apr 2014;50(6):1084-9. doi:10.1016/j.ejca.2014.01.025
101. Ohba K, Miyata Y, Mitsunari K, et al. Alternative Treatment with Every-Other-Day Dosing of Sunitinib for Metastatic Renal Cell Carcinoma: Extended Follow-Up. *Urologia internationalis*. 2022;106(6):623-629. doi:10.1159/000520652
102. Ohba K, Miyata Y, Yasuda T, et al. Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule. *Asia-Pacific journal of clinical oncology*. Jun 2018;14(3):153-158. doi:10.1111/ajco.12849
103. Ohzeki T, Fukasawa S, Komaru A, et al. Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma. *International journal of urology : official journal of the Japanese Urological Association*. Oct 2014;21(10):1065-8. doi:10.1111/iju.12504
104. Rizza L, Sbardella E, Gianfrilli D, et al. Thyroid profile during the alternative Sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma. *Endocrine*. Mar 2020;67(3):597-604. doi:10.1007/s12020-019-02088-4

105. Smaletz O, Chacón M, de Oliveira Koch L, de Carvalho Rocha DR, Cardoso FC. Long-term benefit of sunitinib in patients with metastatic renal cell carcinoma in Latin America: retrospective analysis of patient clinical characteristics. *OncoTargets and therapy*. 2016;9:7309-7314. doi:10.2147/ott.S111137
106. Suo A, Iqbal U, Lim J, et al. Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study. *Clinical genitourinary cancer*. Jun 2017;15(3):e397-e404. doi:10.1016/j.clgc.2017.01.016
107. Tan HS, Li H, Hong YW, et al. Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore. *Clinical genitourinary cancer*. Aug 2015;13(4):e285-e295. doi:10.1016/j.clgc.2014.11.004
108. Teo YL, Chue XP, Chau NM, et al. Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. *Targeted oncology*. Sep 2015;10(3):429-37. doi:10.1007/s11523-014-0349-2
109. Yamada Y, Ohno Y, Kato Y, et al. Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma. *Cancer chemotherapy and pharmacology*. Nov 2019;84(5):987-992. doi:10.1007/s00280-019-03935-x
110. Yildiz I, Sen F, Basaran M, et al. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey. *Japanese journal of clinical oncology*. Dec 2011;41(12):1380-7. doi:10.1093/jjco/hyr151
111. Abogunrin S, Ashaye AO, Cappelleri JC, et al. Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis. *Future oncology (London, England)*. Jun 2019;15(18):2175-2190. doi:10.2217/fon-2018-0858
112. Park SJ, Lee JL, Park I, et al. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. *Chemotherapy*. 2012;58(6):468-74. doi:10.1159/000346484
113. Porta C, Paglino C, Imarisio I, et al. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. *BMC cancer*. Mar 24 2011;11:105. doi:10.1186/1471-2407-11-105
114. Noda S, Otsuji T, Baba M, et al. Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. *Clinical Genitourinary Cancer*. 2015/08/01/ 2015;13(4):350-358. doi:https://doi.org/10.1016/j.clgc.2015.01.007
115. Faivre S, Delbaldo C, Vera K, et al. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer. *Journal of Clinical Oncology*. 2006/01/01 2006;24(1):25-35. doi:10.1200/JCO.2005.02.2194
116. Diekstra MH, Fritsch A, Kanefendt F, et al. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer. *CPT: pharmacometrics & systems pharmacology*. Sep 2017;6(9):604-613. doi:10.1002/psp4.12210
117. Hasskarl J. Everolimus. Recent results in cancer research *Fortschritte der Krebsforschung Progres dans les recherches sur le cancer*. 2018;211:101-123. doi:10.1007/978-3-319-91442-8_8
118. FDA. Label of AFINITOR (everolimus) tablets for oral administration.
119. Research CFDEA. Afinitor (everolimus) tablets clinical pharmacology and bipharmaceutics review.
120. Knoll M, Macher-Goeppinger S, Kopitz J, et al. The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker. *Oncotarget*. Jan 5 2016;7(1):418-32. doi:10.18632/oncotarget.6225
121. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet (London, England)*. Aug 9 2008;372(9637):449-56. doi:10.1016/s0140-6736(08)61039-9
122. Nozawa M, Nonomura N, Ueda T, et al. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice. *Japanese journal of clinical oncology*. Nov 2013;43(11):1132-8. doi:10.1093/jjco/hyt121
123. Maráz A, Csejtei A, Kocsis J, et al. Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results. *Pathology oncology research : POR*. Jan 2019;25(1):149-156. doi:10.1007/s12253-017-0317-0
124. Ravaud A, Urva SR, Grosch K, Cheung WK, Anak O, Sellami DB. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. *European journal of cancer (Oxford, England : 1990)*. Feb 2014;50(3):486-95. doi:10.1016/j.ejca.2013.11.022

125. Tanaka A, Yano I, Shinsako K, et al. Population Pharmacokinetics of Everolimus in Relation to Clinical Outcomes in Patients With Advanced Renal Cell Carcinoma. *Therapeutic drug monitoring*. Dec 2016;38(6):663-669. doi:10.1097/ftd.0000000000000344
126. de Wit D, Schneider TC, Moes DJAR, et al. Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. *Cancer chemotherapy and pharmacology*. 2016/07/01 2016;78(1):63-71. doi:10.1007/s00280-016-3050-6
127. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *New England Journal of Medicine*. 2015;373(19):1803-1813. doi:doi:10.1056/NEJMoa1510665
128. Meybodi SM, Farasati Far B, Pourmolaei A, et al. Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events. *Medical oncology (Northwood, London, England)*. Jul 15 2023;40(8):243. doi:10.1007/s12032-023-02114-6
129. FDA. Label of OPDIVO (nivolumab) injection (Revised on 2/2023).
130. Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. *CPT Pharmacometrics Syst Pharmacol*. Jan 2017;6(1):58-66. doi:10.1002/psp4.12143
131. Clinical reports for OPDIVO - Extension of Indication Advanced Metastatic Renal Cell Carcinoma (2015).
132. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *The New England journal of medicine*. Jun 28 2012;366(26):2443-54. doi:10.1056/NEJMoa1200690
133. Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. *Journal for immunotherapy of cancer*. 2016;4:72. doi:10.1186/s40425-016-0177-2
134. Zhao X, Shen J, Ivaturi V, et al. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types. *Annals of oncology : official journal of the European Society for Medical Oncology*. Feb 2020;31(2):302-309. doi:10.1016/j.annonc.2019.10.015
135. Thana M, Basappa NS, Ghosh S, et al. Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. *Clinical genitourinary cancer*. Jun 2022;20(3):210-218. doi:10.1016/j.clgc.2021.12.003
136. Puszkiel A, Bianconi G, Pasquiers B, et al. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients. *British journal of cancer*. May 2024;130(11):1866-1874. doi:10.1038/s41416-024-02659-x
137. Peer CJ, Heiss BL, Goldstein DA, Goodell JC, Figg WD, Ratain MJ. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. *Journal of clinical pharmacology*. Apr 2022;62(4):532-540. doi:10.1002/jcph.1984
138. FDA. Clinical pharmacology and biopharmaceutic review (nivolumab). Application Number 125554Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000C linPharmR.pdf.
139. Zhang J, Sanghavi K, Shen J, et al. Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies. *CPT Pharmacometrics Syst Pharmacol*. Dec 2019;8(12):962-970. doi:10.1002/psp4.12476
140. FDA-AACR public workshop on optimizing dosages for oncology drug products: quantitative approaches to select dosages for clinical trials. <https://www.aacr.org/professionals/policy-and-advocacy/regulatory-science-and-policy/events/fda-aacr-workshop-optimizing-dosages-for-oncology-drug-products/>
141. Sheiner LB. Learning versus confirming in clinical drug development. *Clinical Pharmacology & Therapeutics*. 1997;61(3):275-291. doi:https://doi.org/10.1016/S0009-9236(97)90160-0
142. Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. *Clin Pharmacokinet*. Sep 2011;50(9):551-603. doi:10.2165/11593320-000000000-00000
143. de Wit D, Guchelaar HJ, den Hartigh J, Gelderblom H, van Erp NP. Individualized dosing of tyrosine kinase inhibitors: are we there yet? *Drug discovery today*. Jan 2015;20(1):18-36. doi:10.1016/j.drudis.2014.09.007

144. Tringale KR, Carroll KT, Zakeri K, Sacco AG, Barnachea L, Murphy JD. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. *Journal of the National Cancer Institute*. May 1 2018;110(5):479-485. doi:10.1093/jnci/djx226
145. Hirsch I, Goldstein DA, Tannock IF, Butler MO, Gilbert DC. Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access. *Nature Medicine*. 2022/11/01 2022;28(11):2236-2237. doi:10.1038/s41591-022-02029-1
146. Chen YH, Wang CC, Chen YY, Wang JH, Hung CH, Kuo YH. Low-dose nivolumab in advanced hepatocellular carcinoma. *BMC cancer*. Nov 8 2022;22(1):1153. doi:10.1186/s12885-022-10271-6
147. Rossi E, Bersanelli M, Gelibter AJ, et al. Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient? *Current Oncology Reports*. 2021/11/08 2021;23(12):147. doi:10.1007/s11912-021-01140-9
148. Zhou L, Reddy MB, Mittapalli RK, Yang J, Yin D. Oncology Combination Dose-Finding Study Design for Targeted and Immuno-Oncology Therapies. *Clinical pharmacology and therapeutics*. Jan 2024;115(1):29-35. doi:10.1002/cpt.3085
149. Venkatakrishnan K, Jayachandran P, Seo SK, van der Graaf PH, Wagner JA, Gupta N. Moving the needle for oncology dose optimization: A call for action. *CPT Pharmacometrics Syst Pharmacol*. Jun 2024;13(6):909-918. doi:10.1002/psp4.13157
150. Rossi E, Bersanelli M, Gelibter AJ, et al. Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient? *Curr Oncol Rep*. Nov 8 2021;23(12):147. doi:10.1007/s11912-021-01140-9
151. Sibbald B, Roland M. Understanding controlled trials: Why are randomised controlled trials important? *BMJ*. 1998;316(7126):201. doi:10.1136/bmj.316.7126.201
152. Bi Y, Liu J, Li F, et al. Model-Informed Drug Development in Pediatric Dose Selection. *The Journal of Clinical Pharmacology*. 2021;61(S1):S60-S69. doi:https://doi.org/10.1002/jcph.1848
153. FDA U. Pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer: guidance for industry. Accessed 05-01-2023, 2023. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetic-based-criteria-supporting-alternative-dosing-regimens-programmed-cell-death-receptor>
154. ter Heine R, van den Heuvel MM, Piet B, et al. A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer. *Targeted Oncology*. 2023/05/01 2023;18(3):441-450. doi:10.1007/s11523-023-00958-6
155. Tang M, Pearson SA, Simes RJ, Chua BH. Harnessing Real-World Evidence to Advance Cancer Research. *Current oncology (Toronto, Ont)*. Feb 2 2023;30(2):1844-1859. doi:10.3390/curroncol30020143
156. Masini C, Vitale MG, Maruzzo M, et al. Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. *Clinical genitourinary cancer*. Feb 2019;17(1):e150-e155. doi:10.1016/j.clgc.2018.10.001

SUPPLEMENTAL MATERIAL 2.1

Literature search strategy

Part A: Dose reduction/alternative regimens

((alternative[tiab] OR adapt*[tiab] OR reduct*[tiab] OR reduce*[tiab] OR reducing*[tiab] OR adjust*[tiab] OR optimisa*[ti] OR optimisi*[ti] OR optimise*[ti] OR optimiz*[tiab] OR minimiz*[tiab] OR minimis*[tiab] OR modif*[tiab] OR personalis*[tiab] OR personaliz*[tiab] OR "Precision Medicine"[Mesh] OR precision*[tiab] OR individualiz*[tiab] OR individualis*[tiab] OR "higher dose"[tiab:~1] OR "lower dose"[tiab:~1] OR "highered dose"[tiab:~1] OR "lowered dose"[tiab:~1] OR "high dose"[tiab:~1] OR "low dose"[tiab:~1] OR "higher dosis"[tiab:~1] OR "lower dosis"[tiab:~1] OR "highered dosis"[tiab:~1] OR "lowered dosis"[tiab:~1] OR "high dosis"[tiab:~1] OR "low dosis"[tiab:~1]) AND ("cabozantinib"[Supplementary Concept] OR "cabozantinib*"[Title/Abstract] OR "pazopanib"[Supplementary Concept] OR "pazopanib*"[Title/Abstract] OR "sunitinib"[MeSH Terms] OR "sunitinib*"[Title/Abstract] OR "axitinib*"[MeSH Terms] OR "axitinib"[Title/Abstract] OR "AG 013736"[Title/Abstract] OR "AG013736"[Title/Abstract] OR "lenvatinib"[Supplementary Concept] OR "lenvatinib*"[Title/Abstract] OR "pembrolizumab"[Supplementary Concept] OR "pembrolizumab*"[Title/Abstract] OR "nivolumab"[MeSH Terms] OR "nivolumab*"[Title/Abstract] OR "ipilimumab"[MeSH Terms] OR "ipilimumab"[Title/Abstract] OR "avelumab"[Supplementary Concept] OR "avelumab*"[Title/Abstract] OR "everolimus"[MeSH Terms] OR "everolimus*"[Title/Abstract] OR "temsirolimus"[Supplementary Concept] OR "temsirolimus*"[Title/Abstract]) AND (mRCC[tiab] OR ("Kidney neoplasms"[majr] OR RCC[tiab] OR ccRCC[tiab] OR ("Kidney"[majr] OR kidney[tiab] OR kidneys[tiab] OR kidneycell*[tiab] OR renal[tiab]) AND (neoplasm*[ti] OR cancer[ti] OR cancers[ti] OR tumor[ti] OR tumors[ti] OR tumour[ti] OR tumours[ti] OR malignan*[ti]))) AND ("Neoplasm Metastasis"[majr] OR metastasis[ti] OR metastase*[ti] OR metastatic[ti] OR Metastasiz*[ti] OR "stage IV Cancer" [ti] OR "secondary"[Subheading] OR "Clear-cell metastatic renal cell carcinoma" [Supplementary Concept]))) NOT ("Review"[Publication Type] OR "Systematic Review" [Publication Type] OR "review"[ti] OR "Letter"[Publication Type] OR "Editorial"[Publication Type] OR "Comment"[Publication Type] OR "Case Reports" [Publication Type] OR "case report"[ti] OR "case study"[ti] OR "Clinical Trial, Phase I" [Publication Type] OR "Clinical Trial, Phase II" [Publication Type] OR "Clinical Trial, Phase III" [Publication Type] OR "phase 1 trial"[ti] OR "phase 1"[ti] OR "phase I"[ti] OR "phase 2"[ti] OR "phase II"[ti] OR "phase 3"[ti] OR "phase III"[ti] OR preclinical[ti] OR animal*[ti] OR mouse[ti] OR mice[ti] OR mus[ti] OR rodent*[ti] OR rat[ti] OR rats[ti] OR "In Vitro Techniques"[Mesh] OR "in vivo"[ti] OR ("Animals"[Mesh]) NOT "Humans"[Mesh]))

Part B: PK models

((("Pkmodel*" [tiab] OR ("Pharmacokinetics" [Mesh] OR pharmacokinetic* [tiab] OR "pharmacokinetic*" [tiab] OR "PK" [tiab]) AND model* [tiab])) AND ("cabozantinib" [Supplementary Concept] OR "cabozantinib*" [Title/Abstract] OR "pazopanib" [Supplementary Concept] OR "pazopanib*" [Title/Abstract] OR "sunitinib" [MeSH Terms] OR "sunitinib*" [Title/Abstract] OR "axitinib*" [MeSH Terms] OR "lenvatinib" [Supplementary Concept] OR "lenvatinib*" [Title/Abstract] OR "pembrolizumab" [Supplementary Concept] OR "pembrolizumab*" [Title/Abstract] OR "nivolumab" [MeSH Terms] OR "nivolumab*" [Title/Abstract] OR "ipilimumab" [MeSH Terms] OR "ipilimumab" [Title/Abstract] OR "avelumab" [Supplementary Concept] OR "avelumab*" [Title/Abstract] OR "everolimus" [MeSH Terms] OR "everolimus*" [Title/Abstract] OR "temsirolimus" [Supplementary Concept] OR "temsirolimus*" [Title/Abstract])) NOT ("Review" [Publication Type] OR "Systematic Review" [Publication Type] OR "review" [ti] OR "Letter" [Publication Type] OR "Editorial" [Publication Type] OR "Comment" [Publication Type] OR "Case Reports" [Publication Type] OR "case report" [ti] OR "case study" [ti] OR preclinical [ti] OR animal* [ti] OR mouse [ti] OR mice [ti] OR mus [ti] OR rodent* [ti] OR rat [ti] OR rats [ti] OR "In Vitro Techniques" [Mesh] OR "in vivo" [ti] OR ("Animals" [Mesh]) NOT "Humans" [Mesh]))

Table S2.1. Labelled dose, alternative dose regimens that used in model-based simulations and simulated percentage therapeutic window achievements results

Drug	Labelled dose	Other dose evaluated in model-informed simulation [§]	Therapeutic window achievement (%) [*]	Efficacy target achievement (%)	Beyond toxicity target (%)
Pazopanib	800 mg QD	-	70	86	16
		600 mg QD	70	76	6
		400 mg QD	51	52	1.0
Axitinib	5 mg BID	-	82	87	5
		10 mg BID	57	94	37
		7 mg BID	75	91	16
		3 mg BID	78	78	0
Cabozantinib	60 mg QD	-	21	100	79
		40 mg QD	38	97	58
		20 mg QD	55	62	7.6
		60 mg QD 2 days on 1 day off	36	99	63
Sunitinib	50 mg 4/2	-	75	89	14
		50 mg 2/1	74	76	2
		37.5 mg QD	56	57	1
		25 mg QD	9	9	0
Everolimus	10 mg QD	-	42	91	49
		5 mg QD	55	66	11
		7.5 mg QD	49	83	34
		5 mg BID	33	96	62
Nivolumab	240 mg Q2W	-	/	100	/
		3 mg/kg Q2W	/	100	/
		360 mg Q3W	/	100	/
		480 mg Q4W	/	99	/

QD, once daily; BID, twice daily; Q2W, once every 2 weeks; Q3W, once every 3 weeks; Q4W, once every 4 weeks; 4/2, 4 weeks on and 2 weeks off treatment; 2/1, 2 weeks on and 1 week off treatment.

[§] The dose regimens that explored in model-informed simulations are generated from the routine clinical practice studies with the nearest tablet/pill/vial strength and one dose level lower. For axitinib and nivolumab, a higher dose level is also considered due to the well tolerability of the labelled dose.

^{*} The percentage of individuals that exposure within the therapeutic window when simulating 1000 individuals per drug per regimen.

SUPPLEMENTAL MATERIAL 2.2

The file could be accessed from <https://github.com/tanzy1995/JCP-supplements/tree/main>.

